ストックスクリーナーアプリを入手
7.82
5.44%
-0.45
アフターアワーズ：
7.84
0.02
+0.26%
Immunitybio Inc (IBRX) 最新ニュース
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - simplywall.st
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat
Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits
IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Finviz
IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
How dovish Fed policy supports ImmunityBio Inc. (26CA) stock2026 Technicals & Weekly Market Pulse Alerts - Naître et grandir
ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN
Vanguard Group Inc. Boosts Stock Position in ImmunityBio, Inc. $IBRX - MarketBeat
How ImmunityBio Inc. stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Entry High Yield Tips - Naître et grandir
Rafferty Asset Management LLC Grows Stake in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Down 3.2%Time to Sell? - MarketBeat
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating - Bitget
ImmunityBio ANKTIVA Milestones Reshape Growth Outlook And Risk Profile - Sahm
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Nasdaq
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout - Yahoo Finance
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses - Yahoo Finance
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026 - Meyka
ImmunityBio Shares Retreat Despite Strong Commercial Momentum - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 10.2%What's Next? - MarketBeat
ImmunityBio Director’s Share Sale Spurs Investigations: Stock Faces Downturn - timothysykes.com
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth - The Chronicle-Journal
ImmunityBio (NASDAQ:IBRX) Shares Gap DownTime to Sell? - MarketBeat
Major Director Share Sale Hits ImmunityBio Stock - StocksToTrade
ImmunityBio (IBRX) Shares Drop Nearly 10% as Investors Digest Recent Earnings - International Business Times Australia
ImmunityBio Faces Increased Investor Skepticism Amid Recent Developments - timothysykes.com
ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target - TipRanks
Piper Sandler raises Immunitybio stock price target on revenue growth - Investing.com
1.76%
0.09%
大文字化:
|
ボリューム (24 時間):